Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 499 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Positive Choice Clear all
Completed Not applicable Interventional

Comparing the Effectiveness of Two Produce Prescription Approaches On Fruit and Vegetable Intake and Food Security, While Exploring Implementation Outcomes Such as Reach, Implementation, Sustainability, and Cost

NCT06263751
View directory record Official record
Conditions
Food Insecurity
Interventions
Product prescription program- NutriConnect Credit, Product prescription program- NutriConnect Delivery
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 99 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 31, 2026, 2:58 PM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Heart Rate Variability Biofeedback Following Traumatic Brain Injury

NCT05913505
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
OSC-
Behavioral
Lead sponsor
Brigham Young University
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Provo, Utah
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 31, 2026, 2:58 PM EDT
Completed Not applicable Interventional Results available

Neurofeedback Impact on Veterans With mTBI

NCT04195685
View directory record Official record
Conditions
Concussion, mTBI, Post-Concussive Symptoms, Chronic Headache, Chronic Insomnia, Chronic Attention Disorder
Interventions
Neurofeedback (NFB)
Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 31, 2026, 2:58 PM EDT
Active, not recruiting Phase 3 Interventional

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

NCT04784715
View directory record Official record
Conditions
Breast Cancer; HER2-positive; Metastatic
Interventions
Trastuzumab deruxtecan, Placebo, Taxane, Pertuzumab, Trastuzumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
30
States / cities
Tucson, Arizona • Springdale, Arkansas • Glendale, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 31, 2026, 2:58 PM EDT
Terminated Phase 2 Interventional Results available

Personalized Treatment Selection for Metastatic Breast Cancer

NCT00780676
View directory record Official record
Conditions
Breast Cancer
Interventions
Dasatinib, AZD6244
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Oct 31, 2026, 2:58 PM EDT
Completed Phase 1Phase 2 Interventional Results available

BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)

NCT01750918
View directory record Official record
Conditions
Cancer
Interventions
Dabrafenib, Trametinib, Panitumumab, 5-fluorouracil
Drug · Device
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
8
States / cities
Scottsdale, Arizona • San Francisco, California • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 31, 2026, 2:58 PM EDT
Completed Not applicable Interventional Results available

Home-Based Diagnosis and Management of Sleep-Related Breathing Disorders in Spinal Cord Injury

NCT01882257
View directory record Official record
Conditions
Obstructive Sleep Apnea, Hypercapnia, Spinal Cord Injury
Interventions
BiPAP, BiPAP/AVAPS (Phillips Respironics)
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 31, 2026, 2:58 PM EDT
Completed Not applicable Interventional

Efficacy Trial of Stress Check-Up

NCT03423394
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Motivational Enhancement Therapy, Treatment as Usual
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 31, 2026, 2:58 PM EDT
Not yet recruiting Phase 1 Interventional

Safety Of A Second Dose Of Tenecteplase In Selected Acute Ischemic Stroke Patients Not Responding To The First Dose

NCT06801054
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)
Drug
Lead sponsor
Memorial Hermann Health System
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 31, 2026, 2:58 PM EDT
Completed Not applicable Interventional

Optimizing Resilience and Coping in HIV Via Internet Delivery

NCT01997008
View directory record Official record
Conditions
HIV Disease, Depression, Affect, Psychological Stress
Interventions
Intervention
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 1, 2020 · Synced Oct 31, 2026, 2:58 PM EDT
Completed Phase 1 Interventional

Study of 68Ga-R10602

NCT06745804
View directory record Official record
Conditions
Locoregionally Recurrent Hormone-receptor Positive Breast Cancer, Metastatic Hormone Receptor Positive Breast Cancer, Hormone Receptor Positive Breast Adenocarcinoma
Interventions
68Ga-R10602 injection
Drug
Lead sponsor
Radionetics Oncology
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Indianapolis, Indiana • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 31, 2026, 2:58 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

NCT04576455
View directory record Official record
Conditions
Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Interventions
Giredestrant, Fulvestrant or an Aromatase Inhibitor (Physician Choice), LHRH Agonist
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Marietta, Georgia • Cleveland, Ohio • Tigard, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 31, 2026, 2:58 PM EDT
Recruiting Phase 3 Interventional

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

NCT05879926
View directory record Official record
Conditions
Breast Cancer
Interventions
Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression
Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
3,960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2034
U.S. locations
1226
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 809 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 31, 2026, 2:58 PM EDT
Completed Not applicable Interventional

Social Networks and Renal Education: Promoting Transplantation

NCT03536858
View directory record Official record
Conditions
End Stage Renal Disease, Living Donor Kidney Transplantation, Renal Dialysis
Interventions
COACH (Communicating about Choices in Transplantation)
Behavioral
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 31, 2026, 2:58 PM EDT
Completed Not applicable Interventional

Development of a Positive Psychology Intervention to Reduce Suicide Risk

NCT01398891
View directory record Official record
Conditions
Suicidal Ideation, Suicide Attempt
Interventions
Positive Psychology Exercises
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Oct 31, 2026, 2:58 PM EDT
Completed Not applicable Interventional Results available

Long-term Behavior Change - 1

NCT00158197
View directory record Official record
Conditions
Amphetamine-related Disorders
Interventions
contingency management voucher
Behavioral
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
2
States / cities
Los Angeles, California • Rancho Cucamonga, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Oct 31, 2026, 2:58 PM EDT
Recruiting Not applicable Interventional

A Patient Activation Approach to Implementing Depression Treatment in Cardiac Patients

NCT07390331
View directory record Official record
Conditions
Depression and CVD
Interventions
iHeart Depcare tool
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 31, 2026, 2:58 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors

NCT05672459
View directory record Official record
Conditions
Solid Tumor
Interventions
Single Injection of IVS-3001- Anti - HLA-G CAR-T cells, Fludarabine phosphate, Cyclophosphamide, leukapheresis
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 31, 2026, 2:58 PM EDT
Terminated Not applicable Interventional

Couple's Retreats for Posttraumatic Stress Disorder

NCT05274061
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Accelerated, Intensive, Multi-Couple Cognitive Behavioral Couples Therapy
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Oct 31, 2026, 2:58 PM EDT
Recruiting Phase 1 Interventional

SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors

NCT07812805
View directory record Official record
Conditions
Selected Advanced Solid Tumors, Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Biliary Tract Cancer (BTC), Gastric Cancer (GC), Esophageal Cancer (EC), Head and Neck Squamous Cell Cancer (HNSCC)
Interventions
SKL35501, SKL35502
Drug · Diagnostic Test
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Glen Burnie, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 31, 2026, 2:58 PM EDT
Not listed Not applicable Interventional

Comparing the Effectiveness of Two Alcohol+Adherence Interventions for HIV+ Youth

NCT01969461
View directory record Official record
Conditions
HIV
Interventions
Motivational Enhancement Therapy (MET)
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
16 Years to 24 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 31, 2026, 2:58 PM EDT
Terminated Phase 2 Interventional Results available

Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies

NCT03717480
View directory record Official record
Conditions
Hematologic Malignancy
Interventions
ClinicMACs
Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 31, 2026, 2:58 PM EDT
Terminated Phase 1 Interventional

Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib

NCT02538627
View directory record Official record
Conditions
Colorectal Cancer, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Interventions
MM-151, MM-121, MM-141, trametinib
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Aurora, Colorado • Sandy Springs, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 31, 2026, 2:58 PM EDT
Terminated Phase 3 Interventional Results available

Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

NCT04797780
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Tamibarotene, Placebo, Azacitidine
Drug
Lead sponsor
Syros Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
22
States / cities
Tucson, Arizona • Los Angeles, California • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 31, 2026, 2:58 PM EDT